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Henoch-Schönlein purpura is a systemic vasculitis, commonly affecting children.
Gastrointestinal manifestations are observed in 50–75% of patients; it is well known
they may occur before skin lesions in about 20% of cases during the first vasculitic
episode. Relapses occur in about one third of patients, typically within 4 months from the
initial presentation and with milder symptoms. We report the case of a 17-year old girl
with an atypical relapse of Henoch-Schönlein purpura, presenting with acute abdominal
symptoms 5 years after the first episode. Esophagogastroduodenoscopy showed
duodenal multiple hyperemic and hemorrhagic lesions. To our knowledge this is the
first case of hemorrhagic-erosive duodenitis representing a relapse of Henoch-Schönlein
purpura occurring several years after the initial episode. Duodenojejunal inflammation
should be considered as primary manifestation of Henoch-Schönlein purpura, not only
during the first episode, but also in relapses. Endoscopy can be helpful for differential
diagnosis, especially in patients with atypical manifestations. Further studies are needed
to evaluate risk factors for Henoch-Schönlein purpura recurrence and the possible role
of fecal calprotectin as an early marker for gastrointestinal involvement.
Keywords: Henoch-Schönlein purpura, duodeno-jejunitis, relapse, atypical presentation, endoscopy
BACKGROUND
Henoch-Schönlein purpura (HSP) is a systemic small vessel vasculitis commonly affecting children.
Gastrointestinal (GI) manifestations are frequent and they generally involve the small intestine.
Duodeno-jejunitis can be the main clinical manifestation of HSP and in about 20% of cases it
may appear before skin lesions during the first episode (1). It may be difficult to diagnose HSP
based merely on GI symptoms if palpable purpura is absent. Relapses of HSP are common and they
usually present as a new flare of cutaneous lesions, followed by gastrointestinal or renal impairment.
The present report describes an unusual late onset relapse of HSP with gastroduodenitis
diagnosed with endoscopy.
CASE PRESENTATION
Presenting Concerns
A 17-year old girl was admitted to a local hospital for acute abdominal symptoms. She had a
previous history of HSP with typical cutaneous and articular manifestations and good response
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to oral steroid therapy, at the age of 12. Ten months after the
first HSP occurrence, she relapsed presenting the same clinical
features. Renal involvement was always absent. At age 16 she
developed erythema nodosum which was successfully treated
with oral steroid therapy.
On admission to the local hospital she presented with fever,
vomiting, diarrhea and epigastric pain. Symptoms had begun
5 days before and had gradually worsened. She was not under
any medications and did not report any recent infection.
Physical examination was unremarkable except for abdominal
pain on deep palpation especially in the epigastric region, without
hepatomegaly or splenomegaly; Blumberg and Murphy signs
were negative. There was no skin rash at admission.
Laboratory analysis showed slightly increased C-reactive
protein (CRP) (2.3 mg/dL, normal value < 0.29 mg/dl). During
hospitalization, gastrointestinal symptoms worsened despite
intravenous (IV) proton pump inhibitor and empiric antibiotic
treatment. Three days after admission, a few petechiae appeared
on arms and feet. The patient was thus transferred to our hospital.
Clinical Findings
On arrival she was febrile and presented continuous projectile
vomiting. Vital parameters were normal except for mild
tachycardia (140 bpm). Few petechial lesions were present on
forearms, hands, and insteps. Lungs and heart examination was
unremarkable. The abdomen was diffusely painful and tender,
especially in upper quadrants, without rebound tenderness
or organomegaly. Rectal examination did not show any
bleeding, anal fissures, ulcers, abscesses, fistulae or scarring.
Musculoskeletal examination was also normal.
Diagnostic Focus and Assessment
Blood exams were unremarkable, except for mild leukocytosis
(leucocytes 18,120/mm3) and elevated CRP (4.36 mg/dL).
Erythrocyte sedimentation rate (ESR), procalcitonin (PCT),
transaminases, total and direct bilirubin, amylase, lipase,
coagulation profile were within normal range. Stool culture,
testing for Rotavirus and Adenovirus, Clostridium difficilis
toxin and antigen were negative. Hemoccult was positive
on three stools specimens. Urinalysis showed no significant
abnormalities. Anti-Saccharomyces cerevisiae antibodies (ASCA)
and anti-neutrophil cytoplasmic antibodies (ANCA), were
performed in the workout for inflammatory bowel diseases
and resulted negative. On the other hand, fecal calprotectin
dosage was elevated (>300 mg/Kg, normal value: <50 mg/Kg).
Immunological laboratory tests (IgG, IgA, IgM levels, IgG
subclasses, and lymphocyte subpopulations) were normal.
Abdomen ultrasound showed scarce peristalsis, slight ascites,
hypervascularization and wall thickening of pylorus and second
portion of duodenum. Plain abdomen X-ray and CT scan showed
no significant abnormalities.
For the persistence of abdominal pain, an
esophagogastroduodenoscopy was performed, which revealed
pyloric edema, multiple hyperemic and hemorrhagic lesions with
round shape in the duodenal bulb and descending duodenum,
some of them were ulcerating (Figures 1, 2). Histological
FIGURE 1 | Esophagogastroduodenoscopy evidence of multiple hyperemic
and hemorrhagic round-shaped lesions in distal duodenum.
FIGURE 2 | Detail of duodenal lesions (PENTAX i-scan imaging).
examination showed active but non-specific inflammation with
eosinophilic component and IgA deposition (Figure 3).
Overall, clinical manifestations, the results of laboratory
analysis and the macroscopic and histopathological aspects of
pylorus and duodenum, prompted the diagnosis of HSP relapse
with initial GI involvement.
Therapeutic Focus and Assessment
On admission, the patient was started on total parenteral
nutrition and IV antibiotic treatment with ceftazidime (150
mg/kg/day IV in three divided doses) and metronidazole (40
mg/kg/day IV in three divided doses).
After endoscopy, high-dose IV methylprednisolone (30
mg/Kg/day) for 3 days, followed by oral steroids (prednisone
1 mg/kg/day) was started with dramatic improvement of
gastrointestinal and cutaneous symptoms, which disappeared
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FIGURE 3 | Histopathology of gastric mucosa showing active inflammation
(Hematoxylin and Eosin staining, 20x magnification).
within a week. Enteral nutrition was gradually started again and
she was discharged on oral prednisone.
Follow-up and Outcome
Four weeks later, abdomen ultrasound did not show any
abnormalities. Periodic urinalysis and fecal occult blood tests
were normal. Oral steroid therapy was gradually tapered in 6
weeks.
At 1 year follow up, the patient was asymptomatic and showed
no recurrence of skin rash or gastrointestinal symptoms.
Written informed consent was obtained from the patient’s
parents for the publication of this case report. As the patient’s age
was 17 years, we also obtained her informed consent.
DISCUSSION
HSP is the most common systemic vasculitis in childhood. The
mean age of presentation is 6 years with most cases in children
under 10 years of age (2).
Diagnosis of HSP is made in a patient with palpable purpura
(mandatory criterion) not related to thrombocytopenia, with
lower limb predominance, in the presence of at least one
of the following: diffuse abdominal pain; any biopsy showing
typically leucocytoclastic vasculitis with predominant IgA
deposit or proliferative glomerulonephritis with predominant
IgA deposit; arthritis or arthralgia; renal involvement (hematuria
and/or proteinuria). For purpura with atypical distribution a
demonstration of an IgA deposition through biopsy is required
(3).
HSP is a leukocytoclastic vasculitis accompanied by IgA
immune complexes within affected organs; the predominant
cell types in the inflammatory infiltrate are neutrophils (4). Its
pathogenesis is still unclear but it is considered a complex disease
contributed by several genetic and environmental factors. No
confirmed genetic loci have been found, although some studies
have described an association with some HLA polymorphisms,
cytokines and adhesion molecules, renin-angiotensin system, ß-
1,3-galactosyltransferase (5). IgA, the main component of the
immune deposits in HSP, can activate the complement through
the mannan-binding lectin and alternative pathways and it can
bind and activate several receptors (transferrin receptor, soluble
receptor and transmembrane receptor of IgA), implicated in
HSP pathogenesis (6). Recently, an aberrant glycosylation of
IgA1 (the most represented IgA subclasses) has been proposed
has an important mechanism in HSP pathogenesis and IgA
nephropathy. As regards triggers of HSP, the majority of HSP
pediatric cases follow a bacterial or viral infection and upper
respiratory tract infections are present in 35–52% of patients. An
association between HSP and vaccines, drugs and malignancies
has also been reported, the last two especially in adults (4). No
recent infection, medication use has been reported in our case
and immunodeficiency/immunodisregulation diseases have been
ruled out by normal immunological workout.
Gastrointestinal symptoms occur in 50–75% of children
with HSP (1). These manifestations result from submucosal
hemorrhages and edema of the bowel wall caused by the
underlying vasculitis (2). The small intestine is the most
frequently involved site in the gastrointestinal tract. The second
portion of duodenum is involved more frequently than the bulb,
with duodeno-jejunal inflammation as predominant feature (4).
Abdominal pain is the most common symptom in HSP and
occurs in 60–65% of patients (7). Pain is typically colicky and
localized to periumbilical and epigastric regions and worsens
after meals, mimicking bowel angina or ischemia. The abdomen
may be tender or resemble an acute abdomen, often resulting in
unnecessary surgery. Vomiting and GI bleeding (gross or occult
blood per rectum) occurs in about one third of pediatric patients
(1, 4, 7).
Rarely, (ileo-ileal) intussusception, bowel wall ischemic
necrosis, intestinal perforation, acute acalculous cholecystitis,
hemorrhagic ascites with serositis, pancreatitis, and biliary
cirrhosis may occur (4, 7).
Endoscopic, radiological, and ultrasound studies are used in
the diagnosis of GI complications in HSP. Abdomen ultrasound
is considered the initial test and reveals bowel wall thickening,
reduced peristalsis and dilated bowel loops; moreover, it can
rule out surgical complications such as intussusception or
perforation. Second-line radiologic exams include CT scan and
MRI (8).
As for our case, endoscopy can provide definitive diagnosis,
especially when abdominal symptoms precede cutaneous lesions
(9). Endoscopic findings include redness, swelling, petechiae,
submucosal hemorrhage, purpura, erosions, and ulcerations of
the mucosa. Several studies demonstrate the role of endoscopy
in GI presentation of vasculitis. Gong et al. (10) demonstrated the
presence of erosion, petechiae, submucosal hemorrhage, or ulcers
in 95.9% of the patients diagnosed as primary vasculitis with
upper GI involvement, and the second portion of the duodenum
was the most frequently involved site. The authors conclude
that combining endoscopic findings with clinical and radiological
features can facilitate diagnosis of vasculitis with upper GI tract
involvement. Kishikawa et al. (11) described two adult patients
presenting with acute GI presentation, whose endoscopic exams
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(colonscopy, capsule endoscopy, single balloon enteroscopy)
showed circular reddish lesions, some of which ulcerating, and
allowed diagnosis of HSP. The authors suggest that these lesions
are a characteristic of HSP in the gastrointestinal tract, including
the small intestine.
Intestinal biopsies show IgA depositions in 64% of patients
and vasculitis may be found in submucosal intestinal vessels
(4). Histological findings range from non-specific inflammation
to ulceration, edema, hemorrhage, and vascular congestion
(4). Several studies show that endoscopic biopsy has low
sensitivity to diagnose vasculitis because most biopsies are
limited to superficial mucosa and do not reach deeper vessels.
However, mucosal biopsies can be essential to exclude other
diseases, such as inflammatory bowel diseases. In the study by
Gong et al. (10), only 5.4% of the 124 biopsies taken from
upper GI tract showed evidence of vasculitis. Zhang et al.
(12) analyzed endoscopic biopsies from 54 patients with HSP
and gastrointestinal symptoms: all the biopsies demonstrated
non-specific inflammation. Our patient’s biopsy did not show
leukocytoclastic vasculitis but it showed IgA deposition. It also
revealed active inflammation with eosinophilic component. The
presence of an eosinophilic infiltrate in HSP duodenitis was also
described by Louie et al. in three of the 16 duodenal biopsies of
HSP patients (13).
In the presence of severe GI symptoms, infectious
gastroenteritis, eosinophilic gastroenteritis, Crohn’s disease,
ulcerative colitis, microscopic polyangiitis, Wegener’s
granulomatosis and immunodeficiency should be considered
in the differential diagnosis (14). Immunodeficiencies should
be considered in cases of frequently relapsing gastrointestinal
symptoms, especially in early onset cases and in association with
frequent infections and hematological alterations. Distinguishing
HSP with GI onset from Crohn’s disease can be challenging.
In our case, the age of the patient, the history of erythema
nodosum, the acute GI presentation and the elevation of fecal
calprotectin could suggest the onset of Crohn’s disease. On the
other side, the previous episode of HSP, major gastroduodenal
involvement and subsequent appearance of petechiae oriented
us toward GI HSP. In these cases, endoscopy is essential to
the differential diagnosis. Compared to HSP, Crohn’s disease
rarely affects duodenum and jejunum, more likely results in
fibrosis and stricture formation, usually does not manifest as
edema and intramural hemorrhage and does not have IgA
deposition (4).
Similarly to our case, recent studies demonstrate that fecal
calprotectin can be elevated in acute phases of gastrointestinal
involvement in HSP. Therefore, it has been proposed as a marker
for early diagnosis of GI involvement in HSP (15, 16).
It is well known that gastrointestinal symptoms may precede
the purpura by up to 2 weeks in about 20% of children presenting
a first HSP episode (1, 14), with the cutaneous rash commonly
occurring about 1 week (average 6.6 days) after the onset of
abdominal pain (17). However, no data are available about
gastrointestinal clinical presentation, without cutaneous lesions,
during relapses.
In most patients, HSP has an excellent prognosis with
spontaneous resolution of symptoms. Relapses occur in about
one third of patients, after an interval of 4 months to 1 year
from the initial presentation (18). Lei et al. (18) defined relapse
as a second HSP diagnosis at least 3 months apart from the first
episode: the definition of this interval was based on findings
from several epidemiological studies. However, according to
previous studies (8, 19), the time elapsed between onset and
relapse is defined as 1 month. Clinical features at the time
of the relapses resemble the ones at disease diagnosis and
in most cases subsequent episodes are milder and shorter
(2, 19).
Risk factors influencing relapses are not definitely established
due to the extreme variability in different studies. Lei et al.
found that renal involvement, underlying allergic rhinitis and
steroid treatment lasting for >10 days are risk factors for
HSP recurrence in children (18). However, results about
long-term effects of steroid use in HSP are discordant and
the relationship between steroid use and recurrence has not
been established (19–21). Therefore, these drugs should be
used with caution in HSP. In the hospital setting, early
corticosteroid exposure is associated with benefits for several
clinically relevant HSP outcomes, specifically those related to
the gastrointestinal manifestations (22). Thus, as in our case,
severe GI manifestations are a common indication for steroid
treatment.
We present the case of a 17-year-old girl transferred to
our hospital for persistent vomiting and epigastric pain.
Surgical emergencies were excluded. As to differentiate
between abdominal HSP relapse and Crohn’s disease an
esophagogastroduodenoscopy with biopsy was performed and
results were suggestive of HSP.
There are previous reports in literature describing
presentation of HSP with duodenitis in children and adults,
whose diagnosis was possible through a high index of suspicion
in front of acute GI manifestations and the findings of
esophagogastroduodenoscopy (7, 14, 23–26).
In our opinion, the case we presented adds several points
of interest compared to previously published cases. First of
all, the patient’s age and the 5-year period between the first
episode of HSP and the relapse are unusual. In addition, clinical
manifestations of the relapse do not resemble the features of the
initial episode and are more severe.
In the literature there is only another case report describing
a patient presenting hemorrhagic-erosive duodenitis as the first
sign of HSP relapse (27). However, the patient had a typical age
for HSP (7 years old), a typical interval between disease onset
and relapse (13 months), and the same clinical features in the 2
episodes. Therefore, if compared to the cited case, our patient still
presents several atypical aspects.
Thus, duodeno-jejunal inflammation should be considered as
primarymanifestation of HSP, not only during the initial episode,
but also in relapses. Endoscopy can support the diagnosis
of gastrointestinal involvement in HSP, especially in patients
without typical skin rash, either in the first or in the relapsing
episodes of the disease.
Further studies are needed to evaluate risk factors for HSP
recurrence and the possible role of fecal calprotectin as an early
marker for GI involvement.
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CONCLUDING REMARKS
The diagnosis of HSP can be challenging, especially when
the abdominal symptoms precede the characteristic palpable
purpura and in atypical clinical scenarios. HSP should be
considered in differential diagnosis for patients with abdominal
pain and intestinal bleeding, even in the absence of initial
cutaneous involvement. Typical endoscopic findings may alert
gastroenterologists to consider this disease.
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